预约演示
更新于：2025-10-31
Luliconazole
卢立康唑
更新于：2025-10-31
概要
基本信息
药物类型 小分子化药 |
别名 Luconac Solution、Luliconazole (JAN/USAN/INN)、Lulifin + [12] |
作用方式 抑制剂 |
作用机制 fungal CYP51A1抑制剂(真菌细胞色素P450家族成员51抑制剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H9Cl2N3S2 |
InChIKeyYTAOBBFIOAEMLL-REQDGWNSSA-N |
CAS号187164-19-8 |
关联
21
项与 卢立康唑 相关的临床试验CTRI/2025/05/087906
Therapeutic Evaluation of a Topical Unani Formulation in Pityriasis Versicolor (Bahaq) and Its Comparative Study with Luliconazole 1 Percent Ointment: A Randomized, Parallel Group, Open-Label, Standard-Controlled Clinical Trial - NIL
IRCT20240711062393N1
Efficacy Evaluation of Loaded Nanostructured Lipid Carriers (NLC) with Luliconazole in Treatment-Resistant Dermatophytosis
CTRI/2024/03/063613
A Comparative study to evaluate the efficacy and safety of topical Luliconazole versus topical Ciclopirox olamine among patients with Tinea corporis/cruris - NIL
100 项与 卢立康唑 相关的临床结果
登录后查看更多信息
100 项与 卢立康唑 相关的转化医学
登录后查看更多信息
100 项与 卢立康唑 相关的专利（医药）
登录后查看更多信息
303
项与 卢立康唑 相关的文献（医药）2025-10-01MYCOPATHOLOGIA
Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis
Article
作者: Noguchi, Hiromitsu ; Fukushima, Satoshi ; Kubo, Masahide ; Kashiwada-Nakamura, Kayo ; Kano, Rui ; Ohara, Sayaka ; Hayashi, Daiki ; Matsumoto, Tadahiko
Chronic hyperkeratotic tinea pedis is a treatment-resistant infection. We evaluated the efficacy of a 3-month course of topical 1% luliconazole in 21 hyperkeratotic tinea pedis patients. The diagnosis was confirmed through microscopy and culture. The lesion area was assessed monthly using a software program. Clinical responses were classified into five categories from "cured" to "no change." Among the isolates, one terbinafine-resistant T. rubrum strain was detected. The mean lesion area decreased significantly over 3 months, with an average improvement rate of 94.1% ± 12.7% and a cure rate of 61.9%. The mean amount of luliconazole used per foot was 27.5 ± 9.7 g monthly. The resistant case showed a partial improvement with topical luliconazole and was successfully treated with oral fosravuconazole. These findings suggest that 1% topical luliconazole is effective for treating hyperkeratotic tinea pedis.
2025-08-05Microbiology Spectrum
Article
作者: Li, Xiaofang ; Liu, Weida ; Xie, Wenting ; Liang, Guanzhao ; Mei, Huan ; Zheng, Hailin ; Kong, Xue ; Ge, Naicen
ABSTRACT:
The worldwide emergence of
Trichophyton indotineae
has garnered significant attention due to its growing resistance to conventional antifungal therapies, posing significant challenges to the effective management of dermatophytosis. The
in vitro
activities of 16 antifungals were tested against 37
T. indotineae
isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute protocol M38-A3. Luliconazole and amorolfine exhibited low MICs, while itraconazole showed moderately decreased susceptibility, making them preferred treatment options. Echinocandins demonstrated favourable
in vitro
activity against
T. indotineae
, but their potential as therapeutic alternatives for recalcitrant dermatophytosis remains uncertain due to pharmacokinetic and pharmacodynamic limitations. In contrast, terbinafine, fluconazole, griseofulvin, oteseconazole, isavuconazole, ravuconazole, and amphotericin B exhibited elevated MICs for many strains, with strong correlations between certain azoles, indicating potential cross-resistance. A difference in the susceptibility to terbinafine and voriconazole between Chinese and Indian isolates was observed. These findings could provide valuable insights into antifungal resistance patterns and help guide treatment strategies for
T. indotineae
infections.
IMPORTANCE:
Trichophyton indotineae
is a novel emerging dermatophyte that has rapidly spread globally in recent years. Its resistance to first-line antifungal agents, particularly terbinafine and fluconazole, has significantly limited treatment options, emphasizing the urgent need for alternative therapies. This study provides comprehensive antifungal susceptibility data for 16 available antifungal agents, offering valuable insights into potential treatment strategies.
2025-07-01JOURNAL OF DERMATOLOGY
Widespread Majocchi's Granuloma Caused by Multidrug‐Resistant Trichophyton rubrum Successfully Treated With Amphotericin B and Posaconazole
Article
作者: Noguchi, Hiromitsu ; Hiruma, Masataro ; Takamori, Kenji ; Kano, Rui ; Suga, Yasushi ; Matsumoto, Tadahiko ; Kimura, Utako
ABSTRACT:
We encountered a 60‐year‐old Japanese female patient with disseminated dermatophytosis caused by terbinafine‐resistant Trichophyton rubrum with mutant SQLE (Leu393Phe substitution). Histopathology showed fungus in the dermis, indicating Majocchi granuloma. Oral fosravuconazole and topical luliconazole were administered for 18 months, resulting in invasive dermatophytosis with a high β‐d‐glucan level of 7320 pg/mL. The MICs of amphotericin B, posaconazole, griseofulvin, itraconazole, voriconazole, ravuconazole, and terbinafine were 0.5, 0.5, 8, 16, 8, 16, and 32 μg/mL, respectively. Amphotericin B for 6 months followed by oral posaconazole for another 6 months cured the disease. Posaconazole may be a promising agent for the treatment of multidrug‐resistant dermatophytes. We present the first reported case of multiazole‐resistant T. rubrum resulting from prolonged fosravuconazole treatment.
100 项与 卢立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 手癣 | 美国 | 2018-02-20 | |
| 甲癣 | 日本 | 2016-01-22 | |
| 皮肤念珠菌病 | 中国 | 2012-06-27 | |
| 真菌病 | 韩国 | 2010-02-01 | |
| 体癣 | 日本 | 2005-07-31 | |
| 股癣 | 日本 | 2005-07-31 | |
| 足癣 | 日本 | 2005-07-31 | |
| 念珠菌病 | 日本 | 2005-04-11 | |
| 癣 | 日本 | 2005-04-11 | |
| 花斑癣 | 日本 | 2005-04-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性皮肤黏膜念珠菌病 | 药物发现 | 美国 | 2011-01-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 75 | (Luliconazole Cream 1%) | 繭遞衊築艱範願製鹽淵(蓋鹹選廠憲積廠蓋膚鬱) = 網願鹽構範鏇艱觸蓋淵 醖膚製構襯襯選窪壓觸 (憲鹽鹽繭簾膚蓋獵壓糧, 2.93) 更多 | - | 2019-11-27 | ||
Vehicle Cream (Vehicle Cream) | 繭遞衊築艱範願製鹽淵(蓋鹹選廠憲積廠蓋膚鬱) = 獵簾遞鹹鏇淵窪鬱醖繭 醖膚製構襯襯選窪壓觸 (憲鹽鹽繭簾膚蓋獵壓糧, NA) 更多 | ||||||
临床4期 | 20 | Omeprazole 40 mg+Luliconazole Cream 1% | 窪簾齋築淵醖蓋鹽襯鹹(鏇淵衊壓遞蓋鬱觸窪願) = 構鬱夢廠鹹憲鹽廠壓餘 夢憲鬱衊簾鑰積構構製 (壓觸製繭襯鏇網遞衊膚, 0) 更多 | - | 2019-11-27 | ||
临床4期 | 30 | (Tinea Pedis) | 鏇網齋選獵壓遞壓構網(製蓋淵觸醖範鏇鏇膚鹽) = 壓壓憲構築襯窪網範齋 窪壓選壓壓觸網鬱窪選 (選壓積齋範鹽壓鹽艱願, 1.71) 更多 | - | 2019-11-27 | ||
(Tinea Cruris) | 鏇觸製醖齋觸醖鬱齋糧(願餘廠襯齋蓋膚鹹膚壓) = 網繭艱齋選衊簾鹹鑰網 襯構觸築壓淵鹽願積餘 (窪遞範衊憲齋遞網積襯, 13.62) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用